Clinical Trials ArenaOriginal article
Teva’s mAb shows benefit in celiac disease study
Phase 2positivePositive
AI Analysis
Summary
Teva announced positive Phase II data for a monoclonal antibody candidate in celiac disease, though Phase III plans have not yet been confirmed.
Clinical Trial Data
Phase
Phase II
Primary Endpoint
Met
Outcome Details
mAb shows benefit in celiac disease
Importance:6/10
Sentiment:
0.65
monoclonal antibodyceliac diseasePhase II dataTeva
Related Companies
Read the original article
Published by Clinical Trials Arena on September 2, 2026 4:22 PM